Menu
Currency
GWAS Study

Multivariate genome-wide association meta-analysis of over 1 million subjects identifies loci underlying multiple substance use disorders.

Hatoum AS, Colbert SMC, Johnson EC et al.

37250466 PubMed ID
GWAS Study Type
647703 Participants
88 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

HA
Hatoum AS
CS
Colbert SMC
JE
Johnson EC
HS
Huggett SB
DJ
Deak JD
PG
Pathak G
JM
Jennings MV
PS
Paul SE
KN
Karcher NR
HI
Hansen I
BD
Baranger DAA
EA
Edwards A
GA
Grotzinger A
TE
Tucker-Drob EM
KH
Kranzler HR
DL
Davis LK
SS
Sanchez-Roige S
PR
Polimanti R
GJ
Gelernter J
EH
Edenberg HJ
BR
Bogdan R
AA
Agrawal A
Chapter II

Abstract

Summary of the research findings

Genetic liability to substance use disorders can be parsed into loci that confer general or substance-specific addiction risk. We report a multivariate genome-wide association meta-analysis that disaggregates general and substance-specific loci for published summary statistics of problematic alcohol use, problematic tobacco use, cannabis use disorder, and opioid use disorder in a sample of 1,025,550 individuals of European descent and 92,630 individuals of African descent. Nineteen independent SNPs were genome-wide significant (P < 5e-8) for the general addiction risk factor (addiction-rf), which showed high polygenicity. Across ancestries, PDE4B was significant (among other genes), suggesting dopamine regulation as a cross-substance vulnerability. An addiction-rf polygenic risk score was associated with substance use disorders, psychopathologies, somatic conditions, and environments associated with the onset of addictions. Substance-specific loci (9 for alcohol, 32 for tobacco, 5 for cannabis, 1 for opioids) included metabolic and receptor genes. These findings provide insight into genetic risk loci for substance use disorders that could be leveraged as treatment targets.

300,789 European ancestry problematic alcohol use individuals, 270,120 European ancestry problematic tobacco use individuals, 46,351 European ancestry cannabis use disorder individuals, 30,443 European ancestry opioid use disorder individuals

Chapter III

Study Statistics

Key metrics and study information

647703
Total Participants
GWAS
Study Type
No
Replicated
European, African American or Afro-Caribbean
Ancestry
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.